Antenatal steroid treatment and adverse fetal effects: What is the evidence?

被引:39
作者
Kay, HH
Bird, IM
Coe, CL
Dudley, DJ
机构
[1] Univ Wisconsin, Dept Obstet & Gynecol, Madison, WI 53706 USA
[2] Univ Wisconsin, Harlow Primate Lab, Madison, WI 53706 USA
[3] Univ Texas, Hlth Sci Ctr, Dept Obstet & Gynecol, San Antonio, TX 78284 USA
关键词
antenatal steroid treatment; adverse fetal effects;
D O I
10.1016/S1071-5576(00)00075-7
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
This article reviews current animal and human data regarding possible adverse fetal effects from antenatal steroid treatment. Although it is now well accepted that such treatment is of benefit to fetal lung development, the potential for adverse fetal outcomes as a result of single or multiple glucocorticoid dosing has not been widely recognized. There ave now growing concerns, based oil animal and some human data, that repeated antenatal doses could lead to a decrease in birth weight, a decrease in fetal brain and other organ size, and abnormal neuronal development. Previous investigations have been hampered by nonstandardization in the type of glucocorticoid, route of delivery, timing of administration, and number of treatment courses. It is recommended that these concerns be addressed through large randomized, controlled clinical trials. In the meantime, it would be prudent to minimize antenatal steroid treatments to a single course with repeated dosing only if there is a persistent threat of preterm delivery. The practice of giving weekly injections of steroids starting at fetal viability and continuing into the third trimester is not supported. Copyright (C) 2000 by the Society for Gynecologic Investigation.
引用
收藏
页码:269 / 278
页数:10
相关论文
共 78 条
  • [1] ABASSI S, 1997, AM J OBSTET GYNECOL, V179, pA138
  • [2] ALLEN VM, 1997, AM J OBSTET GYNECOL, V176, pA136
  • [3] TRANS-PLACENTAL METABOLISM OF DEXAMETHASONE AND CORTISOL IN THE LATE GESTATIONAL-AGE RHESUS-MONKEY (MACACA-MULATTA)
    ALTHAUS, ZR
    BAILEY, JR
    LEAKEY, JEA
    SLIKKER, W
    [J]. DEVELOPMENTAL PHARMACOLOGY AND THERAPEUTICS, 1986, 9 (05): : 332 - 349
  • [4] [Anonymous], 1984, J PEDIATR-US, V104, P259
  • [5] RESPIRATORY-DISEASE IN VERY-LOW-BIRTH-WEIGHT INFANTS AFTER PRENATAL THYROTROPIN-RELEASING-HORMONE AND GLUCOCORTICOID
    BALLARD, RA
    BALLARD, PL
    CREASY, RK
    PADBURY, J
    POLK, DH
    BRACKEN, M
    MOYA, FR
    GROSS, I
    [J]. LANCET, 1992, 339 (8792) : 510 - 515
  • [6] Multiple courses of antenatal corticosteroids and outcome of premature neonates
    Banks, BA
    Cnaan, A
    Morgan, MA
    Parer, JT
    Merrill, JD
    Ballard, PL
    Ballard, RA
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1999, 181 (03) : 709 - 717
  • [7] TOTAL LEUKOCYTE AND NEUTROPHIL COUNT CHANGES ASSOCIATED WITH ANTENATAL BETAMETHASONE ADMINISTRATION IN PREMATURE-INFANTS
    BARAK, M
    COHEN, A
    HERSCHKOWITZ, S
    [J]. ACTA PAEDIATRICA, 1992, 81 (10) : 760 - 763
  • [8] Fetal origins of cardiovascular disease
    Barker, DJP
    [J]. ANNALS OF MEDICINE, 1999, 31 : 3 - 6
  • [9] EFFECTS OF BETAMETHASONE ON FETAL DEVELOPMENT IN THE RABBIT
    BARRADA, MI
    BLOMQUIST, CH
    KOTTS, C
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1980, 136 (02) : 234 - 238
  • [10] BRADLEY BS, 1994, OBSTET GYNECOL, V83, P869